Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.rmed.2020.106114 http://scihub22266oqcxt.onion/10.1016/j.rmed.2020.106114 32795902!7402220!32795902     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Respir+Med 2020 ; 171 (ä): 106114 Nephropedia Template TP {{tp|p=32795902|t=2020. Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review |pdf=|usr=}}{{32795902}} gab.com Text Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review JO: Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=32795902 #FOAvip Coronavirus disease 2019 (COVID-19) is highly infectious. It has been highlighted that if not expertly and individually managed with consideration of the vasocentric features, a COVID-19 patient with an acute respiratory distress syndrome (CARDS) may eventually develop multiorgan failure. Unfortunately, there is still no definite drug for CARDS that is capable of reducing either short-term or long-term mortality and no specific treatments for COVID-19 exist right now. In this narrative review, based on a selective literature search in EMBASE, MEDLINE, Scopus, The Cochrane Library, Web of Science, and Google Scholar and ClinicalTrials.gov, we have examined the emerging evidence on the possible treatment of CARDS. Although numerous pharmacologic therapies to improve clinical outcomes in CARDS have been studied also in clinical trials, none have shown efficacy and there is great uncertainty about their effectiveness. There is still no recommendation for the therapeutic use of any specific agent to treat CARDS because no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale trials. However, there exist a number of drugs that may be useful at least in some patients. The real challenge now is to link the right patient to the right treatment. Twit Text FOAVip Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review ????Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=32795902 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32795902 #FOAvip English Wikipedia <ref>{{Cite pmid|32795902}}</ref> Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review #MMPMID32795902 Matera MG; Rogliani P; Calzetta L; Cazzola M Respir Med 2020[Sep]; 171 (ä): 106114 PMID32795902show ga Coronavirus disease 2019 (COVID-19) is highly infectious. It has been highlighted that if not expertly and individually managed with consideration of the vasocentric features, a COVID-19 patient with an acute respiratory distress syndrome (CARDS) may eventually develop multiorgan failure. Unfortunately, there is still no definite drug for CARDS that is capable of reducing either short-term or long-term mortality and no specific treatments for COVID-19 exist right now. In this narrative review, based on a selective literature search in EMBASE, MEDLINE, Scopus, The Cochrane Library, Web of Science, and Google Scholar and ClinicalTrials.gov, we have examined the emerging evidence on the possible treatment of CARDS. Although numerous pharmacologic therapies to improve clinical outcomes in CARDS have been studied also in clinical trials, none have shown efficacy and there is great uncertainty about their effectiveness. There is still no recommendation for the therapeutic use of any specific agent to treat CARDS because no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale trials. However, there exist a number of drugs that may be useful at least in some patients. The real challenge now is to link the right patient to the right treatment. |*Coronavirus Infections/complications/drug therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/complications/drug therapy[MESH] |*Respiratory Distress Syndrome/etiology/therapy[MESH] |Antiviral Agents/pharmacology[MESH] |Betacoronavirus/drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Humans[MESH] |SARS-CoV-2[MESH]Pharmacological management of COVID-19 patients with ARDS (CARDS): A n(epmc).pdf DeepDyve Pubget Overpricing